restructuring – Page 2

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

3 months ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

4 months ago talkbio0Tagged AB-2100, ArsenalBio, Cell Therapy, Clinical Trials, layoffs, Myers, restructuring, Squibb partnership, Staff

ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership

Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey

4 months ago talkbio0Tagged Drug Industry, layoffs, Myers, Nordisk, Ozempic, restructuring, Wegovy

Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction

X4 Pharma Halves Workforce in Second Round of 2025 Layoffs

4 months ago talkbio0Tagged Administration occupational activities, Changing, Chronic neutropenia, layoffs, restructuring

X4 Pharmaceuticals; layoffs; restructuring; chronic neutropenia; mavorixafor; management changes; biotech

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

4 months ago talkbio0Tagged CEO, competition, Doustdar, eli lilly, Financial cost, Financial savings, layoffs, Nordisk, Ozempic, profit guidance, restructuring, Wegovy, Weight-Loss Agents

Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance

Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

4 months ago talkbio0Tagged asset, Exit, Lundbeck, Market, neuro-rare diseases, neuro-specialty diseases, NewBridge Pharmaceuticals, offloading, partnerships, restructuring, Swixx Group, Zuellig Pharma

Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases

Exelixis Closes Pennsylvania Site, Cuts 130 Jobs in Major Restructuring

4 months ago talkbio0Tagged Alameda Headquarters, cancer drugs, Exelixis, King, layoffs, Pennsylvania, Prussia, restructuring, Site Closure

Exelixis; layoffs; Pennsylvania; King of Prussia; biotech; job cuts; site closure; restructuring; Alameda Headquarters; cancer drugs

Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

4 months ago talkbio0Tagged Advice, competition, cost-cutting, Generic Drugs, Indivior, Opvee divestiture, profit guidance, real-estate, restructuring, Sales - occupational activity

Indivior; job cuts; real-estate; cost-cutting; restructuring; sales guidance; profit guidance; Opvee divestiture; competition; generic drugs

Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan

5 months ago talkbio0Tagged cost-cutting, Keytruda, layoffs, Merck & Co., New Jersey, Pharma Industry, restructuring, WARN notice

Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

5 months ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline